Targeted Learning Ensembles for Optimal Individualized Treatment Rules with Time-to-Event Outcomes
We consider estimation of an optimal individualized treatment rule from observational and randomized studies when a high-dimensional vector of baseline variables is available. Our optimality criterion is with respect to delaying expected time to occurrence of an event of interest (e.g., death or rel...
Gespeichert in:
Hauptverfasser: | , , |
---|---|
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We consider estimation of an optimal individualized treatment rule from
observational and randomized studies when a high-dimensional vector of baseline
variables is available. Our optimality criterion is with respect to delaying
expected time to occurrence of an event of interest (e.g., death or relapse of
cancer). We leverage semiparametric efficiency theory to construct estimators
with desirable properties such as double robustness. We propose two estimators
of the optimal rule, which arise from considering two loss functions aimed at
(i) directly estimating the conditional treatment effect (also know as the blip
function), and (ii) recasting the problem as a weighted classification problem
that uses the 0-1 loss function. Our estimated rules are super learning
ensembles that minimize the cross-validated risk of a linear combination in a
user-supplied library of candidate estimators. We prove oracle inequalities
bounding the finite sample excess risk of the estimator. The bounds depend on
the excess risk of the oracle selector and a doubly robust term related to
estimation of the nuisance parameters. We discuss some important implications
of these oracle inequalities such as the convergence rates of the value of our
estimator to that of the oracle selector. We illustrate our methods in the
analysis of a phase III randomized study testing the efficacy of a new therapy
for the treatment of breast cancer. |
---|---|
DOI: | 10.48550/arxiv.1702.04682 |